News Search Results
Mar 17, 2026, 08:00 ET Flagship Pioneering Appoints Eric Topol as Academic Advisor to Advance Preemptive Health and Medicine Initiative
Sana Biotechnology,
More news about: Flagship Pioneering
Mar 17, 2026, 08:00 ET Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
it has entered into licensing and equity agreements (the "Agreements") with R1 Therapeutics, Inc. ("R1"). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M. R1 is backed by major global kidney care providers, DaVita, one
More news about: Alebund Pharmaceuticals
Mar 17, 2026, 07:32 ET VST BIO Corporation Announces Series A Financing to Advance VB-001 and Adds William Sessa to Board of Directors
SAN DIEGO, March 17, 2026 /PRNewswire/ -- VST BIO Corporation ("VST BIO"), a biotechnology company developing stroke therapeutics, announces the closing of its Series A financing, led by Coefficient Giving, a philanthropic funder and advisor
More news about: VST Bio Corporation
Mar 17, 2026, 06:38 ET MGI Tech and Predica Diagnostics Accelerate Cervical Cancer Screening on DNBSEQ Platforms
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various
More news about: MGI Tech Co., Ltd.
Mar 17, 2026, 06:00 ET Advanced Biotech For Sustainability (AB4S) Coalition Unveils "The Molecule Manifesto," Pinpointing Four Key Pathways to a $1.1 Trillion Biotech Economy
Advanced Biotech for Sustainability (AB4S), a cross-sector coalition that's committed to unlocking the full environmental potential of advanced biotechnology, published its second annual report, "The Molecule Manifesto: Four Priority Molecule Families to Unlock Industrial Biotech Scale." Following last
More news about: Cradle
Mar 17, 2026, 06:00 ET Advanced Biotech For Sustainability (AB4S) Coalition Unveils "The Molecule Manifesto," Pinpointing Four Key Pathways to a $1.1 Trillion Biotech Economy
Advanced Biotech for Sustainability (AB4S), a cross-sector coalition that's committed to unlocking the full environmental potential of advanced biotechnology, published its second annual report, "The Molecule Manifesto: Four Priority Molecule Families to Unlock Industrial Biotech Scale." Following last
More news about: Cradle
Mar 17, 2026, 06:00 ET Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
doi:10.1016/j.molmet.2025.102271About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Mar 17, 2026, 03:46 ET GLP-1 Receptor Agonist Market to Hit USD 78.4 Billion by 2032, Growing at a CAGR of 3.66% with Rising Demand for Metabolic Disease Therapies | MarkNtel Advisors
diabetes and obesity, strong adoption of advanced pharmaceutical therapies, well-established healthcare infrastructure, and the presence of leading biotechnology and pharmaceutical companies actively developing and commercializing GLP-1-based treatments.Global GLP-1 Receptor
More news about: MarkNtel Advisors
Mar 16, 2026, 16:50 ET Cypherpunk Reports Full Year 2025 Financial Results
and foreign tax purposes; and (j) the ability to comply with the continued listing requirements of the Nasdaq Capital Market. With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but
More news about: Cypherpunk Technologies Inc.
Mar 16, 2026, 16:05 ET Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.Company website: www.scinai.comCompany
More news about: Scinai Immunotherapeutics Ltd.
Mar 16, 2026, 13:57 ET Egret Therapeutics Signs Memorandum of Understanding with Genexine Toward Full Ownership of Lead PD-1 Agonist Asset GX-P1 (EGT-101)
clinical stage biotechnology company focused on function preservation following acute injuryNEW YORK, March 16, 2026 /PRNewswire/ -- Egret Therapeutics, Inc. ("Egret"), a clinical-stage biotechnology company developing
More news about: Turret Capital Management
Mar 16, 2026, 12:23 ET Heparin Market Size Worth USD 11.9 Billion by 2032, Exclusive Report by Maximize Market Research
Developments: Sanofi, Pfizer & Baxter Drive Innovation and Global Supply ExpansionIn August 2025, Sanofi announced a strategic biotechnology collaboration to enhance global heparin production efficiency and strengthen supply resilience. In September 2025, Pfizer Inc. launched an
More news about: Maximize Market Research Pvt. Ltd.
Mar 16, 2026, 12:00 ET CJ Schwan's Announces Gregory Yep as Interim CEO
leadership in global cuisine with speed and innovation." Yep has more than three decades of diverse leadership in food science, nutrition and biotechnology across numerous consumer goods and food-related multinational businesses. He first joined CJ in 2023 as chief technology officer, where he helped
More news about: CJ Schwan’s
Mar 16, 2026, 11:33 ET JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
March 16, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that results from the Phase 2b clinical
More news about: NeuroSense
Mar 16, 2026, 11:30 ET Frost & Sullivan Identifies Top 50 Technologies Set to Shape a $1.25-$1.35 Trillion Market Opportunity by 2030
and value creation. According to Vandana Iyer, Research Director at Frost & Sullivan's TechVision practice, advances in digital health and biotechnology are reshaping treatment paradigms while improving pharmaceutical development efficiency."Technologies such as GLP-1 receptor
More news about: Frost & Sullivan
Mar 16, 2026, 11:30 ET Frost & Sullivan Identifies Top 50 Technologies Set to Shape a $1.25-$1.35 Trillion Market Opportunity by 2030
and value creation. According to Vandana Iyer, Research Director at Frost & Sullivan's TechVision practice, advances in digital health and biotechnology are reshaping treatment paradigms while improving pharmaceutical development efficiency."Technologies such as GLP-1 receptor agonists
More news about: Frost & Sullivan
Mar 16, 2026, 08:00 ET Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE
HAE attacks with a significant and longer-lasting therapeutic effect.About Argo BiopharmaArgo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd
Mar 16, 2026, 08:00 ET Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Mar 16, 2026, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 16, 2026, 06:26 ET GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Guided by its mission to 'Make People and Nature Healthier Through Biotechnology', GenScript supports customers across the full innovation lifecycle (biotechnology research, drug discovery, biologics development, and industrial biotechnology applications) with a team of 5,700+ employees serving 200,000+
More news about: GenScript Biotech Corporation
Mar 16, 2026, 06:10 ET GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Guided by its mission to 'Make People and Nature Healthier Through Biotechnology', GenScript supports customers across the full innovation lifecycle (biotechnology research, drug discovery, biologics development, and industrial biotechnology applications) with a team of 5,700+ employees serving 200,000+
More news about: GenScript Biotech Corporation
Mar 16, 2026, 02:00 ET Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche
Mar 16, 2026, 02:00 ET Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche
Mar 15, 2026, 21:53 ET Aphranel nombrada para la lista Forbes China Beauty 100
16 de marzo de 2026 /PRNewswire/ -- Aphranel, marca china de medicina estética regenerativa bajo la empresa SHANGHAI MOYANG BIOTECHNOLOGY, ha sido incluida en la tercera lista Forbes China Beauty 100, publicada por Forbes China, que reconoce a las marcas del sector de la belleza y
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Mar 13, 2026, 14:34 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
(short video)UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel
More news about: Kessler Topaz Meltzer & Check, LLP